CCRL2 Antibody

Code CSB-PA001416
Size US$100
Order now
Image
  • Western Blot analysis of HepG2 cells using CCRL2 Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CCRL2
Alternative Names
CCRL2; CCR11; CCR6; CKRX; CRAM; HCR; C-C chemokine receptor-like 2; Chemokine receptor CCR11; Chemokine receptor X; Putative MCP-1 chemokine receptor
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Synthesized peptide derived from the Internal region of Human CCRL2.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IF 1:200-1:1000
ELISA 1:20000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for CCL19 and chemerin/RARRES2. Does not appear to be a signaling receptor, but may have a role in modulating chemokine-triggered immune responses by capturing and internalizing CCL19 or by presenting RARRES2 ligand to CMKLR1, a functional signaling receptors. Plays a critical role for the development of Th2 responses.
Gene References into Functions
  1. CCRL2 mRNA was not significantly changed in murine and human non-alcoholic steatohepatitis liver. CCRL2 mRNA levels were positively correlated with inflammation, fibrosis and NASH scores in the patients. PMID: 28600126
  2. CCRL2 inhibited the growth of breast cancer cells in vitro and in vivo. PMID: 26487662
  3. in breast cancer, CRAM-A becomes specifically upregulated under inflammatory stimuli and may serve as a potential marker of immune response. PMID: 26563945
  4. these results suggest for the first time that elevated CCRL2 in glioma promotes cell migration and invasion. PMID: 23142225
  5. Considering the newly defined role of CCRL2 in lung dendritic cell trafficking, this atypical chemokine receptor may affect pneumocystis pneumonia through immune regulation and inducing inflammation. PMID: 22046140
  6. demonstration that the homeostatic chemokine CCL19 is a specific ligand for CRAM PMID: 20002784
  7. CCRL2 expression is up-regulated on synovial neutrophils of rheumatoid arthritis patients PMID: 15188357
  8. Results identify chemerin as a natural nonsignaling protein ligand for both human and mouse CCRL2. PMID: 18794339

Show More

Hide All

Subcellular Location
Cell membrane; Multi-pass membrane protein.
Protein Families
G-protein coupled receptor 1 family
Tissue Specificity
Expressed abundantly in immunal tissues such as spleen, fetal liver, lymph node and bone marrow. Strong expression also in lung and heart. Expressed in almost all hematopoietic cells including monocytes, macrophages, PMNs, T-cells (both CD4+ and CD8+), mo
Database Links

HGNC: 1612

OMIM: 608379

KEGG: hsa:9034

STRING: 9606.ENSP00000349967

UniGene: Hs.535713

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*